EGFR and colon carcinoma: Another key regulatory target of DSCR9 within the identified network was EGFR, which was recognized as a widely studied oncogene and an important drug target related to multiple anticancer therapeutics, including gefitinib, erlotinib, afatinib, brigatinib, and icotinib for pulmonary carcinoma and cetuximab for colon carcinoma.